Cingulate (CINGW) Other Accumulated Expenses (2021 - 2026)
Cingulate's (CINGW) quarterly Other Accumulated Expenses came in at $27275.0 in Q2 2026, down 23.35% on a YoY basis from $35586.0 in Q2 2025, and down 68.91% quarter-over-quarter from $87742.0 in Q4 2025.
Analysis
Cingulate (CINGW) Other Accumulated Expenses (2021 - 2026) Analysis & Trends
Cingulate (CINGW) has reported Other Accumulated Expenses for 6 consecutive years, with $27275.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Other Accumulated Expenses fell 23.35% year-over-year to $27275.0; the trailing twelve-month figure through Jun 2026 stood at $27275.0 (down 23.35% YoY), and the FY2025 full-year result was $87742.0, up 55.36% from the prior year.
- Other Accumulated Expenses eased to $27275.0 in Q2 2026 per CINGW's latest filing, from $87742.0 in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $326742.0 in Q3 2022 and bottomed at $16107.0 in Q2 2023.
- Historically, Other Accumulated Expenses has averaged $91560.4 across 5 years, with a median of $55363.0 in 2022.
- The sharpest annual moves came in 2023 and 2024: Other Accumulated Expenses slumped 94.87% in 2023, then jumped 159.66% in 2024.
- Over 5 years, Other Accumulated Expenses stood at $55363.0 in 2022, then rose by 20.83% to $66897.0 in 2023, then retreated by 15.58% to $56476.0 in 2024, then jumped by 55.36% to $87742.0 in 2025, then slumped by 68.91% to $27275.0 in 2026.
- According to Business Quant data, Other Accumulated Expenses over the past three periods registered $27275.0, $87742.0, and $59455.0 for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.10 Bn | 625.34 Bn | 17.26 Bn |
| 2 | AbbVie | 441.68 Bn | 435.11 Bn | 12.70 Bn |
| 3 | Merck | 366.62 Bn | 359.48 Bn | 12.21 Bn |
| 4 | Novartis Ag | 266.55 Bn | 258.86 Bn | 11.24 Bn |
| 5 | Pfizer | 159.14 Bn | 147.45 Bn | 10.94 Bn |
| 6 | Sanofi | 52.40 Bn | 45.02 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 44.07 Bn | 44.07 Bn | - |
| 8 | Incyte | 25.59 Bn | 21.05 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.54 Bn | 18.88 Bn | 683.80 Mn |
| 10 | Cingulate | 100,214.03 | 100,214.03 | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 27,275.00 |
| Dec 31, 2025 | 87,742.00 |
| Sep 30, 2025 | 59,455.00 |
| Jun 30, 2025 | 35,586.00 |
| Mar 31, 2025 | 22,809.00 |
| Dec 31, 2024 | 56,476.00 |
| Sep 30, 2024 | 27,450.00 |
| Jun 30, 2024 | 25,850.00 |
| Mar 31, 2024 | 74,569.00 |
| Dec 31, 2023 | 66,897.00 |
| Sep 30, 2023 | 28,127.00 |
| Jun 30, 2023 | 16,107.00 |
| Mar 31, 2023 | 28,718.00 |
| Dec 31, 2022 | 55,363.00 |
| Sep 30, 2022 | 326,742.00 |
| Jun 30, 2022 | 314,097.00 |
| Mar 31, 2022 | 303,263.00 |
| Dec 31, 2021 | 295,595.00 |